| Literature DB >> 32983127 |
Coen H Wiegman1, Feng Li2, Bernhard Ryffel3, Dieudonnée Togbe3,4, Kian Fan Chung1.
Abstract
Oxidative stress plays an important role in the pathogenesis of chronic obstructive pulmonary disease (COPD) caused by cigarette smoke and characterized by chronic inflammation, alveolar destruction (emphysema) and bronchiolar obstruction. Ozone is a gaseous constituent of urban air pollution resulting from photochemical interaction of air pollutants such as nitrogen oxide and organic compounds. While acute exposure to ozone induces airway hyperreactivity and neutrophilic inflammation, chronic ozone exposure in mice causes activation of oxidative pathways resulting in cell death and a chronic bronchial inflammation with emphysema, mimicking cigarette smoke-induced COPD. Therefore, the chronic exposure to ozone has become a model for studying COPD. We review recent data on mechanisms of ozone induced lung disease focusing on pathways causing chronic respiratory epithelial cell injury, cell death, alveolar destruction, and tissue remodeling associated with the development of chronic inflammation and AHR. The initial oxidant insult may result from direct effects on the integrity of membranes and organelles of exposed epithelial cells in the airways causing a stress response with the release of mitochondrial reactive oxygen species (ROS), DNA, and proteases. Mitochondrial ROS and mitochondrial DNA activate NLRP3 inflammasome and the DNA sensors cGAS and STING accelerating cell death pathways including caspases with inflammation enhancing alveolar septa destruction, remodeling, and fibrosis. Inhibitors of mitochondrial ROS, NLRP3 inflammasome, DNA sensor, cell death pathways, and IL-1 represent novel therapeutic targets for chronic airways diseases underlined by oxidative stress.Entities:
Keywords: COPD; empyema; inflammation; model; oxidative stress; ozone
Mesh:
Substances:
Year: 2020 PMID: 32983127 PMCID: PMC7492639 DOI: 10.3389/fimmu.2020.01957
Source DB: PubMed Journal: Front Immunol ISSN: 1664-3224 Impact factor: 7.561
Mean ozone concentration targets and thresholds in Europe.
| EU target (8 h mean) | 120 | 0.060 |
| EU information threshold | 180 | 0.090 |
| EU alert threshold | 240 | 0.120 |
| Level in United Kingdom | 80 | 0.040 |
| Level in France | 90 | 0.045 |
| Level in Germany | 100 | 0.050 |
| Level in Italy | 130 | 0.065 |
Adapted from: Air quality in Europe – 2019 report. EU, European Union; ppm, parts per million. (.
Dose, duration, and effect of ozone exposures at different ages of rodents.
| 2 ppm | 8 h | Rat | Adult | Decrease ATP synthesis and mtO2 consumption, increase lung mitochondria permeability ( |
| 3 ppm | 8 h | Rat | Adult | Decreased mitochondrial respiration, decrease mtO2 consumption ( |
| 3 ppm | 8 h | Rat | Old | Decreased mitochondrial respiration, decrease mtO2 consumption ( |
| 3 ppm | 3 h | Mouse | Adult | Increased mitochondrial ROS, reduced membrane potential, ETC I, III, V proteins, and ATP content ( |
| 4 ppm | 4 h | Rat | Adult | Decrease mtO2 consumption ( |
| 0.5 ppm | 12 h per day for 7 days | Rat | Young | Increased ROS, decreased ventilatory function ( |
| 0.5 ppm | 12 h per day for 7 days | Rat | Adult | No effects on mitochondria O2 consumption ( |
| 0.5 ppm | 12 h per day for 7 days | Rat | Old | Increased ROS and decreased mitochondria O2 consumption, increased ROS ( |
| 0.8 ppm | 10–20 days | Rat | Adult | Increase number of mitochondria, increase O2 consumption rates ( |
| 2.5 ppm | 3 h, twice a week for 6 weeks | Mouse | Adult | Increased mitochondrial ROS, reduced membrane potential, increased ETC protein II, and IV ( |
| 3 ppm | 3 h, twice a week for 6 weeks | Mouse | Adult | Increased mitochondrial ROS, reduced membrane potential, ETC protein and ATP content ( |
Young = <2 months age, Adult = 2–6 months of age, Old = >6 months of age. ATP, adenosine triphosphate; ETC, electron transport chain; mtO.
Effect of different treatment strategies in ozone-exposed animal models.
| Apocynin | Cellular ROS | Inhibition epithelial cell proliferation | ( |
| Corticosteroids | MAPK | Inhibition of inflammation, AHR | ( |
| H2S | Cellular and mitochondrial ROS | Inhibition of inflammation, ROS, and emphysema | ( |
| iPSC-MSC | Lung | Inhibition of cellular and mitochondrial ROS, normal membrane potential | ( |
| ISO-1 | MIF cytokine | Inhibition of inflammation and AHR | ( |
| MitoTEMPO | Mitochondria | Inhibition mitochondrial ROS, normal complex protein expression | ( |
| MitoQ | Mitochondria | Inhibition of inflammation, AHR, mitochondrial ROS and mitochondrial dysfunction | ( |
| VX-765 | NLRP3 inflammasome | Inhibition of inflammation and AHR Inhibition of inflammation, AHR, emphysema | ( |
AHR, airway hyperreactivity; H.
Figure 1Ozone-mediated effects on intracellular pathways involved in cell injury and inflammation. Overview of the effects of ozone in in vitro and in vivo models. The biphasic response to ozone starts with an immediate intracellular reactive oxygen species (ROS) and inflammation independent phase that is induced by extracellular oxidative stress. ROS induces membrane damage with changes in cell membrane integrity, disruption of tight junctions, epithelial cell stress, and death. Inflammatory mediators including IL-25 and IL-33 are released and attract innate immune cells such as natural killer (NK) cells and innate lymphoid type 2 (ILC2) cells. Cell death and release of dsDNA can induce an interferon (IFN) inflammation response via the cGAS/STING pathway. Processes activated during the intracellular ROS and inflammation-dependent phase of the effects of ozone include transcription factor-mediated inflammatory response and the activation of the antioxidant defense mechanism. Several inhibitors have been shown to prevent or treat the pro-inflammatory gene expression and subsequently inhibit the inflammatory response, including the JNK inhibitor, SP600125, and the p38 MAPK inhibitor, SD282. In addition, activation of the endogenous antioxidant defense system involving HADC2, Keap1, and Nrf2 may be sufficient to counteract the oxidant stress during acute ozone exposure but may be overwhelmed during chronic ozone exposure. Treatment with the antioxidant N-acetylcysteine (NAC) also reduces the inflammatory response, by scavenging of intracellular ROS with subsequent reduction of cytokine and chemokine production. Mitochondrial oxidative stress and mitochondrial dysfunction contribute to apoptotic processes and the activation of the NLRP3 inflammasome further enhancing the inflammatory response. Several treatment strategies targeting the mitochondria have been able to reduce or prevent the mitochondrial oxidative-induced dysfunction. These include several mitochondrial-targeted antioxidants such as MitoQ, MitoTEMPO, and SS-31. In addition, stem cell therapy with induced pluripotent stem cell-derived mesenchymal stem cells (iPSC-MSCs) prevented ozone-induced mitochondrial dysfunction and inflammation which may result from direct interaction and mitochondrial transfer between the iPSC-MSCs and airway cells. Treatment with the caspase-1 inhibitor VX765 and hydrogen sulfide (H2S) prevent the activation of the inflammasome and reduces inflammation and mitochondrial oxidative stress. The MIF inhibitor ISO-1 blocks the ozone exposure induced inflammation and airway hyperreactivity and might have an impact on the corticosteroid insensitivity present in chronic ozone exposed lungs. Corticosteroids reduce inflammation induced by acute ozone exposures but fail to affect these processes in the steroid insensitive chronic ozone exposed lung. The ozone exposure driven intracellular processes contribute to the inflammatory cytokine and chemokine production, immune cell recruitment, and eventually the development of airway hyperreactivity, airway obstruction, airway remodeling, emphysema, autoimmunity, and steroid insensitivity which are hallmarks of COPD. cGAS, cyclic GMP-AMP synthase; COPD, chronic obstructive pulmonary disease; dsDNA, double stranded DNA; H2S, hydrogen sulfide; HDAC2, histone deacetylase 2; HIF-1α, hypoxia inducible factor subunit 1α; IFN, interferon; IL, interleukin; ILC2, innate lymphoid cells type 2; iPSC-MSC, induced pluripotent stem cell-derived mesenchymal stem cell; ISO-1, (S,R)3-(4-hydroxyphenyl)-4,5-dihydro-5-isoxazole acetic acid methyl ester; Keap1, Kelch-like ECH associated protein 1; MAPK, mitogen activated kinase; MKP-1, mitogen-activated protein kinase phosphatase-1; MIF, macrophage migration inhibitory factor; MKP-1, mitogen-activated protein kinase phosphatase-1; NAC, N-acetylcysteine; NFκB, nuclear factor κB; NK, natural killer cell; NLRP3, NACHT, LRR, and PYD domains-containing protein 3; Nrf2, nuclear factor (erythroid-derived 2)-like 2; ROS, reactive oxygen species; SD282, p38 MAPK inhibitor; SP600125, c-jun NH2 terminal kinase (JNK) inhibitor; SS-31, d-Arg-2', 6'-dimethyltyrosine-Lys-Phe-NH2 mitochondrial antioxidant; STING, stimulator of interferon genes; TNF-α, tumor necrosis factor -α; VX765, Belnacasan, caspase 1 inhibitor.